AVTX
NasdaqAVALO THERAPEUTICS, INC.
Basic Materials · Pharmaceutical Preparations
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
🔒 price chart needs market-data feed$5.4M
2021
$18.1M
2022
$1.9M
2023
$441,000
2024
$59,000
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$59,000
Net Income$-78.3M
Gross Profit—
Oper Income$-72.9M
EPS (dil)$-5.84
Rev/sh$0.00
FCF/sh$-0.98
Book/sh$1.58
Gross M—
Oper M-123601.7%
Profit M-132642.4%
FCF M-87378.0%
ROE-94.2%
ROA-67.2%
ROIC-88.8%
R&D/Rev9807.9%
Rev Y/Y-86.6%
Rev 3Y CAGR-85.2%
EPS Y/Y72.1%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+78.8%
Current Ratio8.14
Quick Ratio8.14
Debt/Eq0.18
Int Coverage—
Net Debt$800,144 cash
Total Debt$15.3M
Cash & Eq$16.1M
Total Assets$116.5M
Oper CF$-51.5M
Capex$95,000
Free CF$-51.6M
Buybacks—
Equity$83.0M
Liabilities$33.4M
Shs Outstand0.05B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $5.4M | $18.1M | $1.9M | $441,000 | $59,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-82.1M | $-37.4M | $-27.4M | $-68.5M | $-72.9M |
| Net Income | $-84.4M | $-41.7M | $-31.5M | $-35.1M | $-78.3M |
| Diluted EPS | — | $-1063.00 | $-113.58 | $-20.91 | $-5.84 |
| Operating Cash Flow | $-70.9M | $-26.8M | $-30.7M | $-49.1M | $-51.5M |
| Free Cash Flow | $-71.0M | $-26.8M | — | — | — |
COMMUNITY · $AVTX0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.